Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Orthopaedic Research

• Publication date

  2003-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0736-0266(02)00095-5PMID 12507581
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.

  2001cited by this paper
• Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.

  2001cited by this paper
• Gene Expression of Insulin-Like Growth Factors and Receptors in Neoplastic Prostate Tissues: Correlation with Clinico-pathological Parameters

  2001cited by this paper
• Secretory products from PC‐3 and MCF‐7 tumor cell lines upregulate osteopontin in MC3T3‐E1 cells

  2000cited by this paper
• gp130 Cytokine family and bone cells.

  2000cited by this paper
• Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy.

  2000cited by this paper
• Quantitative small‐animal surrogate to evaluate drug efficacy in preventing wear debris‐induced osteolysis

  2000cited by this paper
• Tumor Necrosis Factor (cid:97) Stimulates Osteoclast Differentiation by a Mechanism Independent of the ODF/RANKL–RANK Interaction

  2000cited by this paper
• Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function.

  1999cited by this paper
• Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment

  1999cited by this paper
• Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process.

  1999cited by this paper
• Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism.

  1999cited by this paper
• Characterization of the role of IL‐6 in the progression of prostate cancer

  1999cited by this paper
• Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies.

  1998cited by this paper
• The Role of IL‐6 Type Cytokines and Their Receptors in Bonea a

  1998cited by this paper
• Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells.

  1998cited by this paper
• Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage.

  1998cited by this paper
• The role of IL-6 type cytokines and their receptors in bone.

  1998cited by this paper
• Mechanisms, Hypotheses and Questions Regarding Prostate Cancer Micrometastases to Bone

  1998cited by this paper
• Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue.

  1997cited by this paper
• Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma.

  1997cited by this paper
• Mechanisms of the development of osteoblastic metastases

  1997cited by this paper
• Prostate‐derived soluble factors block osteoblast differentiation in culture

  1996cited by this paper
• Preclinical models of prostate cancer.

  1996cited by this paper
• Differential effects and glucocorticoid potentiation of bone morphogenetic protein action during rat osteoblast differentiation in vitro.

  1996cited by this paper
• Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer.

  1996cited by this paper
• The effects of bone morphogenetic protein-2, -4, and -6 on differentiation of rat osteoblast cells in vitro.

  1995cited by this paper
• Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3).

  1995cited by this paper
• Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells

  1994cited by this paper
• Steroid-growth factor interaction in human prostate cancer. 1. Short-term effects of transforming growth factors on growth of human prostate cancer cells.

  1994cited by this paper
• Lack of the latent transforming growth factor beta binding protein in malignant, but not benign prostatic tissue.

  1993cited by this paper
• Osteoblastic metastasis in advanced prostate cancer.

  1993cited by this paper
• Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer.

  1992cited by this paper
• Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis.

  1992cited by this paper
• Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia.

  1992cited by this paper
• Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts.

  1991cited by this paper
• Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up.

  1991cited by this paper
• Morphometric evidence for bone resorption and replacement in prostate cancer.

  1991cited by this paper
• Distribution of bony metastases in prostatic carcinoma.

  1990influential reference
• Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures.

  1988cited by this paper
• Effects of human prostatic mitogens on rat bone cells and fibroblasts.

  1987cited by this paper
• Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype.

  1987cited by this paper
• Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia

  1983cited by this paper
• Mechanisms of lytic and blastic metastatic disease of bone.

  1982cited by this paper
• Prostatic osteoblastic factor.

  1979cited by this paper
• Establishment and characterization of a human prostatic carcinoma cell line (PC-3).

  1979cited by this paper
• Mechanisms of bone destruction in the development of skeletal metastases

  1976cited by this paper

• The role of proinflammatory cytokines and CXC chemokines (CXCL1–CXCL16) in the progression of prostate cancer: insights on their therapeutic management

  2024cites this paper
• An Extracellular Matrix Overlay Model for Bioluminescence Microscopy to Measure Single-Cell Heterogeneous Responses to Antiandrogens in Prostate Cancer Cells

  2024cites this paper
• Targeting sex steroid biosynthesis for breast and prostate cancer therapy

  2023cites this paper
• Role of Interleukin-1 family in bone metastasis of prostate cancer

  2022cites this paper
• Prostate cancer cell‑derived spondin 2 boosts osteogenic factor levels in osteoblasts via the PI3K/AKT/mTOR pathway.

  2022cites this paper
• In vitro engineering of a bone metastases model allows for study of the effects of antiandrogen therapies in advanced prostate cancer

  2021cites this paper
• Cytokines and Chemokines as Mediators of Prostate Cancer Metastasis

  2020cites this paper
• High Levels of BMP2 Promote Liver Cancer Growth via the Activation of Myeloid-Derived Suppressor Cells

  2020cites this paper
• Cellular and Molecular Progression of Prostate Cancer: Models for Basic and Preclinical Research

  2020cites this paper
• Androgen Receptor-CaMKK2 Axis in Prostate Cancer and Bone Microenvironment

  2018cites this paper
• Feedback regulation loop between bonemorphogenetic proteins and theirantagonists in prostate cancer and theimplication in bone metastasis

  2018cites this paper
• XENOGRAFT MODEL OF HUMAN BONE METASTATIC PROSTATE CANCER CROSS REFERENCE TO RELATED APPLICATIONS

  2017cites this paper
• Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer

  2016cites this paper
• Oncodynamic Changes in Skeleton

  2016cites this paper
• Mouse models for studying prostate cancer bone metastasis.

  2016cites this paper
• Osteoblasts Are the Centerpiece of the Metastatic Bone Microenvironment

  2016cites this paper
• Exosomes from the tumor microenvironment as reciprocal regulators that enhance prostate cancer progression

  2016cites this paper
• Oncodynamics: Effects of Cancer Cells on the Body

  2016cites this paper
• Association Between BMP-2 and Carcinogenicity

  2015cites this paper
• The regulatory role of osteoblasts in castration-resistant growth of prostate cancer

  2015cites this paper
• Eular Textbook on Rheumatic Diseases

  2015cites this paper
• Tumor-associated Endo180 requires stromal-derived LOX to promote metastatic prostate cancer cell migration on human ECM surfaces

  2015cites this paper
• BMP9 inhibits the bone metastasis of breast cancer cells by downregulating CCN2 (connective tissue growth factor, CTGF) expression

  2014cites this paper
• Personalized Medicine and Imaging Applications of ImmunoPET : Using 124 I-Anti-PSCA A 11 Minibody for Imaging Disease Progression and Response to Therapy in Mouse Xenograft Models of Prostate Cancer

  2014cites this paper
• Applications of ImmunoPET: Using 124I-Anti-PSCA A11 Minibody for Imaging Disease Progression and Response to Therapy in Mouse Xenograft Models of Prostate Cancer

  2014cites this paper
• Do androgen deprivation drugs affect the immune cross-talk between mononuclear and prostate cancer cells?

  2014cites this paper
• Neuroendocrine Differentiation of Prostate Cancer Metastases Evidenced “in Vivo” by 68Ga-DOTANOC PET/CT: Two Cases

  2014cites this paper
• Anti-PSCA minibody for immunoPET imaging of prostate cancer in preclinical models

  2013cites this paper
• Differential Expression of the RANKL/RANK/OPG System Is Associated with Bone Metastasis in Human Non-Small Cell Lung Cancer

  2013cites this paper
• The RANKL/RANK system as a therapeutic target for bone invasion by oral squamous cell carcinoma (Review).

  2013cites this paper
• EUROPEAN ACADEMIC RESEARCH, VOL

  2013cites this paper
• The "bone morphogenic proteins" pathways in bone and joint diseases: translational perspectives from physiopathology to therapeutic targets.

  2013cites this paper
• Molecular and Cellular Pathobiology Interleukin-1 b Promotes Skeletal Colonization and Progression of Metastatic Prostate Cancer Cells with Neuroendocrine Features

  2013cites this paper
• Xenograft, Transgenic, and Knockout Models of Prostate Cancer

  2013cites this paper
• EULAR Textbook on Rheumatic Diseases

  2012cites this paper
• Macrophage-Mediated Lymphangiogenesis: The Emerging Role of Macrophages as Lymphatic Endothelial Progenitors

  2012cites this paper
• The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer.

  2012cites this paper
• TGFβ1–Endo180‐dependent collagen deposition is dysregulated at the tumour–stromal interface in bone metastasis

  2012cites this paper
• Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion.

  2011cites this paper
• Experimental models for the development of new medical treatments in prostate cancer.

  2011cites this paper
• Zoledronic Acid Preserves Bone Structure and Increases Survival but Does Not Limit Tumour Incidence in a Prostate Cancer Bone Metastasis Model

  2011influential citation
• Suppression of invasion and metastasis of prostate cancer cells by overexpression of NDRG2 gene.

  2011cites this paper
• Effects of the bone morphogenetic protein binding protein spp24 (secreted phosphoprotein 24 kD) on the growth of human lung cancer cells

  2011cites this paper
• Steps in prostate cancer progression that lead to bone metastasis

  2011cites this paper
• Bone‐metastatic prostate carcinoma favors mesenchymal stem cell differentiation toward osteoblasts and reduces their osteoclastogenic potential

  2011cites this paper
• Etablissement d'un nouveau modèle pérclinique de cancer de la prostate et identification de biomarqueurs de résistance au docetaxel

  2011cites this paper
• A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions

  2011cites this paper
• Role of bone morphogenetic proteins in human prostate cancer pathogenesis and development of bone metastases: immunohistochemical study.

  2010cites this paper
• Independent and cooperative roles of tumor necrosis factor‐α, nuclear factor‐κB, and bone morphogenetic protein‐2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3‐E1 osteoblast‐like cells

  2010cites this paper
• The cancer‐related Runx2 protein enhances cell growth and responses to androgen and TGFβ in prostate cancer cells

  2010cites this paper
• Mechanistic Role of RANKL in Cancer-induced Bone Diseases and Development of a Targeted Therapy to Inhibit this Pathway

  2010cites this paper
• Myc interacts with Max and Miz1 to repress C/EBPδ promoter activity and gene expression

  2010cites this paper
• New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target?

  2009cites this paper
• Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.

  2009cites this paper
• Biomatériaux et angiogenèse : Utilisation dans les métastases et la reconstruction osseuses

  2009cites this paper
• Histophysiologie du microenvironnement osseux conditionné par l'intoxication au tetradifon et par les métastases osseuses ostéolytiques induites par cellules Wlaker 256/B

  2009cites this paper
• Expression of RANK‐ligand in prostate cancer cell lines

  2009cites this paper
• A single pretreatment by zoledronic acid converts metastases from osteolytic to osteoblastic in the rat

  2009cites this paper
• RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis

  2008cites this paper
• Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions

  2008cites this paper
• Interactions between microenvironment and cancer cells in two animal models of bone metastasis

  2008cites this paper
• RANKL/RANK/OPG: key therapeutic target in bone oncology.

  2008cites this paper
• Characterization of Osteolytic, Osteoblastic, and Mixed Lesions in a Prostate Cancer Mouse Model Using 18F-FDG and 18F-Fluoride PET/CT

  2008cites this paper
• Expression of receptor activator of nuclear factor κ-B ligand (RANKL) in neoplasms of dogs and cats

  2007cites this paper
• Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases.

  2007cites this paper
• Bone morphogenetic proteins and their receptor signaling in prostate cancer.

  2007cites this paper
• A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration.

  2007cites this paper
• Expression of receptor activator of nuclear factor kappa-B ligand (RANKL) in neoplasms of dogs and cats.

  2007cites this paper
• Micro-CT combined with bioluminescence imaging: a dynamic approach to detect early tumor-bone interaction in a tumor osteolysis murine model.

  2007cites this paper
• Key roles of the OPG–RANK–RANKL system in bone oncology

  2007cites this paper
• Xenograft Models of Human Prostate Cancer

  2007cites this paper
• Tumor metastasis to bone

  2007influential citation
• Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases

  2007cites this paper
• Assessing Tumor Growth and Distribution in a Model of Prostate Cancer Metastasis using Bioluminescence Imaging

  2006cites this paper
• Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.

  2006influential citation
• Mixed Metastatic Lung Cancer Lesions in Bone Are Inhibited by Noggin Overexpression and Rank:Fc Administration

  2006influential citation
• Modèles animaux de perte osseuse bénigne et maligne utilisable pour l?évaluation de biomatériaux

  2006cites this paper
• The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.

  2005cites this paper
• The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone.

  2005cites this paper
• Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.

  2005cites this paper
• Receptor activator of nuclear ??B ligand and osteoprotegerin: where are we now and what about future treatment uses?

  2005cites this paper
• BM18: A novel androgen‐dependent human prostate cancer xenograft model derived from a bone metastasis

  2005cites this paper
• Cancer Treatment and Research

  2005cites this paper
• Inhibition of prostate cancer-meditated osteoblastic bone lesions by the low-calcemic analog 1alpha-hydroxymethyl-16-ene-26,27-bishomo-25-hydroxy vitamin D3.

  2005cites this paper
• Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases

  2005cites this paper
• Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo.

  2005cites this paper
• The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone

  2005cites this paper
• Influence of BMPs on the Formation of Osteoblastic Lesions in Metastatic Prostate Cancer

  2005cites this paper
• Monitoring of skeletal progression of prostate cancer by GFP imaging, X‐ray, and serum OPG and PTHrP

  2005cites this paper
• Spiculated periosteal response induced by intraosseous injection of 22Rv1 prostate cancer cells resembles subset of bone metastases in prostate cancer patients

  2005cites this paper
• In vivo real‐time imaging of TGF‐β‐induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer

  2004cites this paper
• Prostate cancer bone metastases promote both osteolytic and osteoblastic activity

  2004cites this paper
• InVivoReal-Time Imagingof TGF-b-Induced TranscriptionalActivationof theRANKLigandGene Promoter in Intraosseous ProstateCancer

  2004cites this paper
• Bone Morphogenetic Proteins: Regeneration of Bone and Beyond

  2004cites this paper
• Bone morphogenetic proteins and cancer

  2004cites this paper
• IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology.

  2004cites this paper
• Opg, RANKl, and RANK in cancer metastasis: expression and regulation.

  2004cites this paper
• The RANKL system and the development of tumor-induced bone disease: lessons from pre-clinical models.

  2004cites this paper
• Modulation of prostate cancer growth in bone microenvironments

  2004influential citation
• RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.

  2004cites this paper